NEW FDA APPROVALS
TODAY'S HEADLINES
FDA approved dronabinol oral solution (Syndros), a liquid formulation of the pharmaceutical cannabinoid dronabinol, a pharmaceutical version of tetrahydrocannabinol (THC). Read more |
|
Expanding access to buprenorphine, a medication to treat opioid use disorder, is just one of several new actions announced by HHS to combat the opioid epidemic. Read more
|
CONTINUING PHARMACY EDUCATION
This month's CE activity, "Expanding vaccination rates through pharmacist-initiated patient identification and assessment," is open for pharmacists and pharmacy technicians.
The goal of this activity is to educate pharmacists and pharmacy technicians about current vaccine recommendations so that they can identify adolescent and adult patients who may need vaccinations. Readers will also gain knowledge about where to obtain information about current vaccine recommendations.
Pharmacists and pharmacy technicians can earn up to 2 hours of CPE credit for completing this knowledge-based activity from the University of Connecticut School of Pharmacy and Drug Topics. More
|
EDITOR'S PICK
A new drug recently approved by FDA to treat chronic hepatitis C virus (HCV) infection enters a competitive, lucrative market headed up by Gilead Science's Sovaldi and Harvoni, as well as AbbVie's Viekira Pak. Read more
|
|
|
